Literature DB >> 30069183

PARP Inhibitors in Breast Cancer: Why, How, and When?

Angelo Paradiso1, Eleni Andreopoulou2, Pierfranco Conte3,4, Alexandru Eniu5, Mahasti Saghatchian6.   

Abstract

Entities:  

Year:  2018        PMID： 30069183      PMCID： PMC6062717          DOI： 10.1159/000490746

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  5 in total

1.  San Antonio Breast Cancer Symposium 2016.

Authors:  Katherine Gourd
Journal:  Lancet Oncol       Date:  2016-12-16       Impact factor: 41.316

2.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Authors:  Helen Davies; Dominik Glodzik; Sandro Morganella; Lucy R Yates; Johan Staaf; Xueqing Zou; Manasa Ramakrishna; Sancha Martin; Sandrine Boyault; Anieta M Sieuwerts; Peter T Simpson; Tari A King; Keiran Raine; Jorunn E Eyfjord; Gu Kong; Åke Borg; Ewan Birney; Hendrik G Stunnenberg; Marc J van de Vijver; Anne-Lise Børresen-Dale; John W M Martens; Paul N Span; Sunil R Lakhani; Anne Vincent-Salomon; Christos Sotiriou; Andrew Tutt; Alastair M Thompson; Steven Van Laere; Andrea L Richardson; Alain Viari; Peter J Campbell; Michael R Stratton; Serena Nik-Zainal
Journal:  Nat Med       Date:  2017-03-13       Impact factor: 53.440

3.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Authors:  Sibylle Loibl; Joyce O'Shaughnessy; Michael Untch; William M Sikov; Hope S Rugo; Mark D McKee; Jens Huober; Mehra Golshan; Gunter von Minckwitz; David Maag; Danielle Sullivan; Norman Wolmark; Kristi McIntyre; Jose J Ponce Lorenzo; Otto Metzger Filho; Priya Rastogi; W Fraser Symmans; Xuan Liu; Charles E Geyer
Journal:  Lancet Oncol       Date:  2018-02-28       Impact factor: 41.316

4.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

5.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Authors:  Andrew Tutt; Holly Tovey; Maggie Chon U Cheang; Sarah Kernaghan; Lucy Kilburn; Patrycja Gazinska; Julie Owen; Jacinta Abraham; Sophie Barrett; Peter Barrett-Lee; Robert Brown; Stephen Chan; Mitchell Dowsett; James M Flanagan; Lisa Fox; Anita Grigoriadis; Alexander Gutin; Catherine Harper-Wynne; Matthew Q Hatton; Katherine A Hoadley; Jyoti Parikh; Peter Parker; Charles M Perou; Rebecca Roylance; Vandna Shah; Adam Shaw; Ian E Smith; Kirsten M Timms; Andrew M Wardley; Gregory Wilson; Cheryl Gillett; Jerry S Lanchbury; Alan Ashworth; Nazneen Rahman; Mark Harries; Paul Ellis; Sarah E Pinder; Judith M Bliss
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440
  5 in total
  1 in total

Review 1.  Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.

Authors:  Ami N Shah; Otto Metzger; Cynthia Huang Bartlett; Yuan Liu; Xin Huang; Massimo Cristofanilli
Journal:  Oncologist       Date:  2020-03-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.